Single treatment of ENTPD2 inhibitors, ARL67156 and POM-1, markedly reduced growth of Hepa1-6-derived HCC in C57BL/6 syngeneic model (Fig. 6a). The gene discussed is ENTPD2; the disease is hepatocellular carcinoma.